Ventripoint Announces Extension and Up Size of Non-Brokered Convertible Debenture Unit Private Placement

Core Points - Ventripoint Diagnostics Ltd. is seeking approval from the TSX Venture Exchange to extend the deadline for its non-brokered private placement of unsecured convertible debentures to November 2, 2025 [1] - The company plans to increase the size of the offering from $500,000 to $560,000 [2] - Each unit in the offering consists of one unsecured convertible debenture with a principal amount of $1,000 and 9,000 common share purchase warrants [2] - The convertible debentures can be converted into common shares at a price of $0.11 per share [3] - Each warrant allows the holder to purchase one common share at a price of $0.14 until December 31, 2027 [3] - The debentures will mature on December 31, 2027, and will bear an interest rate of 10%, payable semi-annually [4] - Proceeds from the offering will be used for operational costs, sales and marketing, hiring key personnel, and general working capital [5] - All securities issued will be subject to a hold period of four months plus one day from the closing date of the offering [6] Company Overview - Ventripoint has established itself as a leader in applying AI technology to echocardiography [8] - The company's VMS+ products utilize proprietary knowledge-based reconstruction technology, providing accurate cardiac measurements comparable to MRI [8] - Ventripoint's products are designed to enhance patient care and are compatible with ultrasound systems from various vendors, supported by regulatory approvals in the U.S., Europe, and Canada [9]